Genscript Biotech Corporation announced that Dr. Zhang Fangliang has been appointed as an non-executive Director of the Company with effect from 2 May 2022. Upon the establishment of the risk management committee of the Board and the strategy committee of the Board as set out in this announcement below, Dr. Zhang has also been appointed as the chairman of the risk management committee and the strategy committee. Dr. Zhang, a non-executive Director, has been appointed as a member and the chairman of the Risk Management Committee; Mr. Guo Hongxin, an independent non-executive Director, and Mr. Pan Jiuan, an independent non-executive Director, have been appointed as members of the Risk Management Committee, with effect from 2 May 2022.

Dr. Zhang, a non-executive Director of the Board, has been appointed as a member and the chairman of the Strategy Committee; Mr. Pan Yuexin, a non-executive Director and Ms. Wang Jiafen, a non-executive Director, have been appointed as members of the Strategy Committee, with effect from 2 May 2022.